Teva Pharmaceuticals USA, Inc. v. Sandoz, Inc.
Carter Phillips of the Sidley Austin firm representing Mylan Inc. in the case of Teva Pharmaceuticals USA v. Sandoz, departs after arguments at the U.S. Supreme Court in Washington October 15, 2014.
Supreme Court divided in battle over Teva MS drug patent | Reuters.com
Sandoz and Teva invalidate blockbuster apixaban patent and SPC - JUVE Patent
Teva Pharmaceuticals v. Sandoz - Inside the Case - YouTube
Teva Pharmaceuticals v. Sandoz: New Rules for Claim Construction Review | WilmerHale
Supreme Court weighs generic drug dispute - Deseret News
Practice Group
Webinar: Teva v. Sandoz SCOTUS Decision | News & Events | Goodwin Procter
Teva Pharmaceuticals USA, Inc. v. Sandoz, Inc. - Podcast | The Federalist Society
United States Court of Appeals for the Federal Circuit
JUST OUT - Molecular weights at the Supreme Court - Teva v Sandoz - The IPKat
Intellectual Property Alert:
Teva v. Sandoz -- Is Deferential Review a Boon for Patent Trolls? | McDonnell Boehnen Hulbert & Berghoff LLP - JDSupra
Teva v. Sandoz & The PTAB | Patents Post-Grant
Patent Docs: IPO Webinar on Teva v. Sandoz
Teva Pharmaceuticals v. Sandoz: Supreme Court Sides with Teva in Patent Case, Holds That Appeals Court Must Review Factual Findings Underlying Claim Construction for “Clear Error” – Policy & Medicine
Claim Construction, Findings of Fact, and Indefiniteness in the Wake of Teva v. Sandoz
Teva Pharmaceuticals USA, Inc. v. Sandoz, Inc., 135 S.Ct. 831 (2015): Case Brief Summary - Quimbee
Teva v. Sandoz: Supreme Court Rules That, In Reviewing Patent Claim Constructions on Appeal, Factual Determinations Derived From Extrinsic Evidence Must Be Given “Clearly Erroneous” Deference - Workman Nydegger
The Impact of Teva Pharmaceuticals v. Sandoz on Patent Claim Construction in the District Courts - YouTube
Prof. Lisa Ouellette Explains SCOTUS Patent Case Teva v. Sandoz - Legal Aggregate - Stanford Law School
